BioMarin and Sarepta bicker over DMD data; Kite gets a head start on CAR-T pricing talk;

@FierceBiotech: J&J gets $116M to help hustle along new Ebola vaccine. Article | Follow @FierceBiotech

@JohnCFierce: We are slowly ramping up Asia reporting this month ahead of FiercePharmaAsia launch in Feb. Good time to start sending embargoed news my way. | Follow @JohnCFierce

@DamianFierce: $ENTA gets $50M for EU approval of $ABBV's hep C combo. From #JPM15, here's what they're going to do with it. More | Follow @DamianFierce

> At this week's JP Morgan Healthcare Conference, BioMarin ($BMRN) CEO Jean-Jacques Bienaime touted the Duchenne muscular dystrophy-treating drisapersen, acquired in its buyout of Prosensa, as superior to a rival drug from Sarepta ($SRPT), sparking a testy exchange between the two companies. Story

> Kite Pharma ($KITE), a contender in the novel space of CAR-T therapies for cancer, says its early-stage candidate could sell for $150,000 per treatment once it hits the market, undercutting analyst expectations for the class of drugs. More

> AbbVie's ($ABBV) combination hepatitis C treatment won European approval, triggering a $50 million payout for partner Enanta Pharmaceuticals ($ENTA). News

Medical Device News

@FierceMedDev: FDA, CDC investigating death, illnesses from IV bags intended for training. News | Follow @FierceMedDev

@VarunSaxena2: J&J says fishy phone calls recruiting women to file vaginal mesh-related suits warrant an investigation. More | Follow @VarunSaxena2

@EmilyWFierce: Gilead blazes ahead in hep C pricing battle with two new PBM deals. Report | Follow @EmilyWFierce

> Bill introduced in Congress to simplify marketing of research use only devices and diagnostics. Story

> Medical device, diagnostic venture investment at $2.7B, highest since 2008. More

Pharma News

@FiercePharma: Boehringer mulls sale of generic plant as stateside shakeup continues. More | Follow @FiercePharma

@CarlyHFierce: With Rytary approval in the bag, Impax Labs scouts buyouts in CNS, generics. Article | Follow @CarlyHFierce

> Gilead blazes ahead in hep C pricing battle with two new PBM deals. More

> Depomed picks up U.S. Nucynta rights as J&J's cast-off moves continue. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.